ATE389668T1 - Tumorantigen - Google Patents
TumorantigenInfo
- Publication number
- ATE389668T1 ATE389668T1 AT01984425T AT01984425T ATE389668T1 AT E389668 T1 ATE389668 T1 AT E389668T1 AT 01984425 T AT01984425 T AT 01984425T AT 01984425 T AT01984425 T AT 01984425T AT E389668 T1 ATE389668 T1 AT E389668T1
- Authority
- AT
- Austria
- Prior art keywords
- peptide
- tumor antigen
- polynucleotide
- tumor antigens
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 102000025850 HLA-A2 Antigen Human genes 0.000 abstract 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000231814 | 2000-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE389668T1 true ATE389668T1 (de) | 2008-04-15 |
Family
ID=18724591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01984425T ATE389668T1 (de) | 2000-07-31 | 2001-07-30 | Tumorantigen |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US7148326B2 (de) |
| EP (1) | EP1306431B1 (de) |
| JP (1) | JP4900884B2 (de) |
| AT (1) | ATE389668T1 (de) |
| AU (1) | AU2002227498A1 (de) |
| CA (1) | CA2417570C (de) |
| DE (1) | DE60133287T2 (de) |
| ES (1) | ES2304398T3 (de) |
| WO (1) | WO2002010369A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060035291A1 (en) * | 2001-09-18 | 2006-02-16 | Kyogo Itoh | Method of detecting cellular immunity and application thereof to drugs |
| JP4721903B2 (ja) * | 2004-01-29 | 2011-07-13 | 大日本住友製薬株式会社 | 新規腫瘍抗原蛋白質及びその利用 |
| US20080200088A1 (en) * | 2007-02-21 | 2008-08-21 | Chong Pyung An | Method for reducing interference fringes in a display device |
| KR101294514B1 (ko) | 2007-09-18 | 2013-08-12 | 가부시키가이샤 그린 펩티드 | Ctl 유도제 조성물 |
| EP2123748A1 (de) * | 2008-05-20 | 2009-11-25 | Institut Pasteur | 2'-5'-Oligoadenylat-Synthetase 3 zur Vorbeugung und Behandlung von positivgerichteten einsträngigen RNA-Virusinfektionen |
| AU2010238858A1 (en) | 2009-04-22 | 2011-12-08 | Merck Patent Gmbh | Antibody fusion proteins with modified FcRn binding sites |
| AU2010268367B2 (en) | 2009-07-02 | 2016-10-20 | Ith Immune Therapy Holdings Ab | Exosome based treatment of cancer |
| WO2011108628A1 (ja) * | 2010-03-03 | 2011-09-09 | 東レ株式会社 | 胃癌検出用マーカー及び胃癌検出方法 |
| JP5897035B2 (ja) * | 2010-12-14 | 2016-03-30 | ユニバーシティ オブ メリーランド,ボルチモア | 汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法 |
| JPWO2013031756A1 (ja) * | 2011-08-29 | 2015-03-23 | 東レ株式会社 | 大腸癌または食道癌の検出用マーカー及び検査方法 |
| JP6283861B2 (ja) | 2012-09-11 | 2018-02-28 | オンコセラピー・サイエンス株式会社 | Ube2tペプチドおよびそれを含むワクチン |
| EP2934532B1 (de) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel |
| EP2966092A4 (de) | 2013-03-08 | 2016-11-16 | Taiho Pharmaceutical Co Ltd | Neuartiges peptid mit 5 verknüpften ctl-epitopen |
| AU2014337643B2 (en) | 2013-10-21 | 2017-07-13 | Taiho Pharmaceutical Co., Ltd. | Novel four-CTL epitope-joined peptide |
| HRP20210698T1 (hr) | 2015-12-22 | 2021-09-17 | Immatics Biotechnologies Gmbh | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma |
| GB201522667D0 (en) * | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| WO2017194170A1 (en) * | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| WO2019004415A1 (ja) * | 2017-06-30 | 2019-01-03 | 国立大学法人大阪大学 | 末梢血t細胞の腫瘍細胞傷害活性を指標とする腫瘍免疫療法の効果予測方法 |
| JP7086980B2 (ja) | 2017-10-26 | 2022-06-20 | 大塚製薬株式会社 | イノシトールリン酸含有組成物 |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| AU2019218729B2 (en) | 2018-02-06 | 2025-12-04 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Car t細胞療法のための配列決定法 |
| TWI805792B (zh) | 2018-06-29 | 2023-06-21 | 日商大鵬藥品工業股份有限公司 | 抗腫瘤劑及其評估方法 |
| KR20220120627A (ko) | 2019-12-26 | 2022-08-30 | 다이호야쿠힌고교 가부시키가이샤 | 수술 후 보조 요법제 |
| IL295063A (en) | 2020-02-04 | 2022-09-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Chimeric antigen receptors (car) against dinitrophenol |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874231A (en) * | 1994-08-22 | 1999-02-23 | Mcgill University | Methods of screening for non-hormone compounds which effect modulation of polypeptide translation |
| AU1110297A (en) * | 1995-12-12 | 1997-07-03 | Kyowa Hakko Kogyo Co. Ltd. | Novel dnas, novel polypeptides and novel antibodies |
| US5936078A (en) * | 1995-12-12 | 1999-08-10 | Kyowa Hakko Kogyo Co., Ltd. | DNA and protein for the diagnosis and treatment of Alzheimer's disease |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| JP2000189168A (ja) * | 1998-12-28 | 2000-07-11 | Hiroshi Handa | 新規転写伸長抑制因子 |
| EP1206536A2 (de) * | 1999-08-17 | 2002-05-22 | Sagami Chemical Research Center | Menschliche proteine mit hydrophoben domänen und dafür kodierende dnas |
-
2001
- 2001-07-30 AU AU2002227498A patent/AU2002227498A1/en not_active Abandoned
- 2001-07-30 DE DE60133287T patent/DE60133287T2/de not_active Expired - Lifetime
- 2001-07-30 AT AT01984425T patent/ATE389668T1/de not_active IP Right Cessation
- 2001-07-30 ES ES01984425T patent/ES2304398T3/es not_active Expired - Lifetime
- 2001-07-30 JP JP2002516288A patent/JP4900884B2/ja not_active Expired - Lifetime
- 2001-07-30 EP EP01984425A patent/EP1306431B1/de not_active Expired - Lifetime
- 2001-07-30 CA CA2417570A patent/CA2417570C/en not_active Expired - Lifetime
- 2001-07-30 WO PCT/JP2001/006526 patent/WO2002010369A1/ja not_active Ceased
-
2003
- 2003-01-30 US US10/353,929 patent/US7148326B2/en not_active Expired - Lifetime
-
2006
- 2006-10-05 US US11/543,088 patent/US7404270B2/en not_active Expired - Lifetime
- 2006-10-05 US US11/543,065 patent/US7524930B2/en not_active Expired - Lifetime
- 2006-10-05 US US11/543,089 patent/US7432354B2/en not_active Expired - Lifetime
- 2006-10-05 US US11/543,066 patent/US7408037B2/en not_active Expired - Lifetime
- 2006-10-05 US US11/543,087 patent/US7427660B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE60133287T2 (de) | 2009-03-26 |
| US20070031433A1 (en) | 2007-02-08 |
| EP1306431B1 (de) | 2008-03-19 |
| ES2304398T3 (es) | 2008-10-16 |
| EP1306431A1 (de) | 2003-05-02 |
| US7427660B2 (en) | 2008-09-23 |
| US7524930B2 (en) | 2009-04-28 |
| DE60133287D1 (de) | 2008-04-30 |
| US7408037B2 (en) | 2008-08-05 |
| US7148326B2 (en) | 2006-12-12 |
| US20070031431A1 (en) | 2007-02-08 |
| US20030175288A1 (en) | 2003-09-18 |
| US20070071767A1 (en) | 2007-03-29 |
| AU2002227498A1 (en) | 2002-02-13 |
| US20070031432A1 (en) | 2007-02-08 |
| CA2417570A1 (en) | 2003-01-31 |
| US7404270B2 (en) | 2008-07-29 |
| US20070066804A1 (en) | 2007-03-22 |
| US7432354B2 (en) | 2008-10-07 |
| EP1306431A4 (de) | 2004-08-18 |
| WO2002010369A1 (en) | 2002-02-07 |
| CA2417570C (en) | 2010-12-07 |
| JP4900884B2 (ja) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60133287D1 (de) | Tumorantigen | |
| CY1105597T1 (el) | Ανοσοθεραπευτικες μεθοδοι χρησιμοποιωντας επιτοπους των wt-1 και gata-1 | |
| DK2316940T3 (da) | Fokuserede biblioteker af genpakker | |
| FI950665A0 (fi) | Melanoomaan liittyvä antigeeninen polypeptidi, sen epitooppeja ja melanoomarokotteita | |
| DE60142689D1 (de) | Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen | |
| EP1731605A4 (de) | Aus wt1 stammende krebsantigenpeptide | |
| DE69910580D1 (de) | Von der telomerase abgeleitete antigene peptide | |
| AU5810201A (en) | Immunogenic polypeptides encoded by mage minigenes and uses thereof | |
| WO2002074795A3 (en) | Oligomeric complexes of chimeric proteins with enhanced immunogenic potential | |
| DE60044193D1 (en) | Tumor antigen | |
| DK1370284T3 (da) | Bakteriofag-medieret immunisering | |
| NO922421D0 (no) | Collagenbindende protein, samt fremstilling derav | |
| DE69928925D1 (de) | Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper | |
| WO2002044202A3 (fr) | Peptides immunogeniques mutes derives de r9m, polynucleotides les codant et leurs usages therapeutiques | |
| ATE451461T1 (de) | Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper | |
| WO1999057277A3 (en) | Basb019 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses | |
| WO2003008450A1 (en) | Tumor antigen | |
| CO5280140A1 (es) | Antigeno (c42) asociado a tumores | |
| CY1105820T1 (el) | Basb027 πρωτεϊνες και γονιδια απο moraxella catarrhalis, αντιγονα, αντισωματα και χρησεις | |
| ATE397069T1 (de) | Basb205 polypeptide und dafür kodierende polynukleotide | |
| MY107451A (en) | Cloning and expression of a rhoptry associated protein of p.falciparum | |
| ATE443715T1 (de) | Polypeptide aus haemophilus influenza | |
| ATE480250T1 (de) | Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion | |
| ATE293693T1 (de) | Moraxella catarrhalis antigen basb117 | |
| ATE293692T1 (de) | Moraxella catarrhalis antigen basb120 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |